한글목차

통증 관리 시장 - 조사 범위

TMR 조사 보고서 '세계의 통증 관리 시장'은 2025-2035년 예측 기간 동안 시장 지표에 대한 가치 있는 인사이트를 얻기 위해 과거 및 현재의 성장 동향과 기회를 연구합니다. 본 보고서는 2025년을 기준 연도, 2035년을 예측 연도로 설정하여 세계의 통증 관리 치료제 시장 수익과 예측을 제공합니다. 또한 2025-2035년 세계의 통증 관리 시장 연평균 성장률(CAGR%)도 제공합니다.

본 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 의견 형성자들과 인터뷰를 실시했습니다. 2차 연구는 주요 업체들의 제품 문헌, 연차 보고서, 보도 자료 및 관련 문서를 참조하여 통증 관리 시장을 파악했습니다.

본 보고서는 세계의 통증 관리 치료 시장 경쟁 구도를 조사했습니다. 세계의 통증 관리 시장에서 사업을 전개하는 주요 기업이 확인되고 각 기업이 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무 현황, 최근 동향, SWOT 분석은 본 보고서에서 프로파일링된 세계의 통증 관리 시장 참여자들의 속성입니다.

세계 통증 관리 시장 보고서에서 다루는 주요 질문

• 세계의 통증 관리 시장 비즈니스 기회는 무엇인가?
• 시장의 주요 촉진요인, 시장 성장 억제요인, 기회, 위협은 무엇인가?
• 예측 기간 동안 가장 빠른 CAGR로 성장하는 지역 시장은 어디인가?
• 2035년 세계에서 가장 높은 수익을 올릴 것으로 예상되는 부문은 무엇인가?
• 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상되는 부문은 무엇인가?
• 세계 시장에서 사업 전개하는 각 기업 시장 포지션은 무엇인가?

통증 관리 시장 - 조사 목적 및 조사 방법

본 조사 보고서는 세계의 통증 관리 시장에 대해 조사 및 분석한 보고서입니다. 본 보고서는 연구 목적과 시장 내 주요 공급업체 및 유통업체, 제품 승인을 위한 규제 환경에 대한 상세한 설명을 제공합니다.

독해 편의성을 위해 보고서는 장별 구성으로 편성되었으며, 각 부분은 소단위로 세분화되었습니다. 보고서는 적절히 배치된 방대한 양의 그래프와 표로 구성됩니다. 주요 부문의 실제 및 예상 값을 시각적으로 표현한 내용은 독자에게 시각적 매력을 제공합니다. 이는 또한 과거와 예측 기간 말 기준 주요 부문의 시장 점유율 비교를 가능하게 합니다.

본 보고서에서는 세계의 통증 관리 시장을 제품, 최종 사용자, 지역별로 분석했습니다. 각 기준의 주요 부문을 상세하게 조사하고 2035년 말 시점의 각 부문에 대한 시장 점유율을 제공합니다. 이러한 가치 있는 인사이트는 시장 관계자들이 세계 통증 관리 시장에 대한 투자에 대한 충분한 정보를 바탕으로 비즈니스 의사 결정을 내릴 수 있습니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 세계의 통증 관리 시장 분석과 예측(2020-2035년)

제5장 주요 인사이트

• 주요 지역 및 국가 규제 상황
• 시장 동향
• Porter's Five Forces 분석
• PESTEL 분석
• 최종 사용자를 위한 주요 구매 지표
• 브랜드와 가격 분석
• 파이프라인 분석
• 주요 질환의 역학

제6장 세계 시장 분석과 예측 : 약제 클래스별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 약제 클래스별(2020-2035년)
  • 항경련제
  • 항우울제
  • 마취약
  • 비스테로이드성 항염증제(NSAID)
  • 오피오이드
  • 편두통 치료제
  • 기타
• 시장의 매력 : 약제 클래스별

제7장 세계 시장 분석과 예측 : 약제 유형별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 약제 유형별(2020-2035년)
  • 시판약(OTC)
  • 처방약
• 시장의 매력 : 약제 유형별

제8장 세계 시장 분석과 예측 : 통증 유형별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 통증 유형별(2020-2035년)
  • 급성 통증
  • 만성 통증
• 시장의 매력 : 통증 유형별

제9장 세계 시장 분석과 예측 : 투여 경로별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 투여 경로별(2020-2035년)
  • 경구
  • 비경구
  • 국소
  • 기타
• 시장의 매력 : 투여 경로별

제10장 세계 시장 분석과 예측 : 적응증별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 적응증별(2020-2035년)
  • 관절염 통증
  • 골절
  • 암 통증
  • 만성 요통
  • 섬유근통증
  • 편두통
  • 근육 염좌
  • 신경장애성 통증
  • 수술 후 통증
  • 기타
• 시장의 매력 : 적응증별

제11장 세계 시장 분석과 예측 : 유통 채널별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 유통 채널별(2020-2035년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 시장의 매력 : 유통 채널별

제12장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 : 지역별

제13장 북미 시장 분석과 예측

• 미국
• 캐나다

제14장 유럽 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 스위스
• 네덜란드
• 기타 유럽

제14장 유럽 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 스위스
• 네덜란드
• 기타 유럽

제15장 아시아태평양 시장 분석과 예측

• 중국
• 일본
• 인도
• 호주 및 뉴질랜드
• 한국
• 기타 아시아태평양

제16장 라틴아메리카 시장 분석과 예측

• 브라질
• 멕시코
• 아르헨티나
• 기타 라틴아메리카

제17장 중동 및 아프리카 시장 분석과 예측

• GCC 국가
• 남아프리카
• 기타 중동 및 아프리카

제18장 경쟁 구도

• 시장기업 : 경쟁 매트릭스(기업 등급 및 규모별)
• 시장 점유율 분석 : 기업별(2024년)
• 기업 프로파일
  • Pfizer Inc.
  • Eli Lilly and Company
  • GSK plc
  • Merck &Co., Inc.
  • Novartis AG
  • Johnson &Johnson Services, Inc.
  • Abbott
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • AstraZeneca
  • Endo, Inc.
  • Bayer AG
  • Sanofi
  • Viatris Inc
  • Haleon plc
  • Impax Laboratories, Inc.
  • Lupin Limited

영문목차

Pain Management Therapeutics Market- Scope of Report

TMR's report on the global Pain Management Therapeutics Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Pain Management Therapeutics Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Pain Management Therapeutics Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Pain Management Therapeutics Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Pain Management Therapeutics Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Pain Management Therapeutics Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Pain Management Therapeutics Market .

The report delves into the competitive landscape of the global Pain Management Therapeutics Market . Key players operating in the global Pain Management Therapeutics Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Pain Management Therapeutics Marketprofiled in this report.

Key Questions Answered in Global Pain Management Therapeutics MarketReport:

• What are the opportunities in the global Pain Management Therapeutics Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Pain Management Therapeutics Market- Research Objectives and Research Approach

The comprehensive report on the global Pain Management Therapeutics Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Pain Management Therapeutics Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Pain Management Therapeutics Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pain Management Therapeutics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pain Management Therapeutics Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory Landscape across Key Regions/Countries
• 5.2. Market Trends
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTEL Analysis
• 5.5. Key Purchase Metrics for End-users
• 5.6. Brand and Pricing Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology of Major Diseases

6. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Class

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Class, 2020 to 2035
  • 6.3.1. Anticonvulsants
  • 6.3.2. Antidepressants
  • 6.3.3. Anaesthetics
  • 6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 6.3.5. Opioids
  • 6.3.6. Anti-migraine Agents
  • 6.3.7. Other
• 6.4. Market Attractiveness By Drug Class

7. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 7.3.1. Over-the-Counter (OTC) Drugs
  • 7.3.2. Prescription Drugs
• 7.4. Market Attractiveness By Drug Type

8. Global Pain Management Therapeutics Market Analysis and Forecasts, By Pain Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Pain Type, 2020 to 2035
  • 8.3.1. Acute Pain
  • 8.3.2. Chronic Pain
• 8.4. Market Attractiveness By Pain Type

9. Global Pain Management Therapeutics Market Analysis and Forecasts, By Route of Administration

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
  • 9.3.4. Others
• 9.4. Market Attractiveness By Route of Administration

10. Global Pain Management Therapeutics Market Analysis and Forecasts, By Indication

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Indication, 2020 to 2035
  • 10.3.1. Arthritic Pain
  • 10.3.2. Bone Facture
  • 10.3.3. Cancer Pain
  • 10.3.4. Chronic Back Pain
  • 10.3.5. Fibromyalgia
  • 10.3.6. Migraine
  • 10.3.7. Muscle Sprain/Strain
  • 10.3.8. Neuropathic Pain
  • 10.3.9. Post-Operative Pain
  • 10.3.10. Others
• 10.4. Market Attractiveness By Indication

11. Global Pain Management Therapeutics Market Analysis and Forecasts, By Distribution Channel

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
• 11.4. Market Attractiveness By Distribution Channel

12. Global Pain Management Therapeutics Market Analysis and Forecasts, By Region

• 12.1. Key Findings
• 12.2. Market Value Forecast By Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness By Region

13. North America Pain Management Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 13.2.1. Anticonvulsants
  • 13.2.2. Antidepressants
  • 13.2.3. Anaesthetics
  • 13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 13.2.5. Opioids
  • 13.2.6. Anti-migraine Agents
  • 13.2.7. Other
• 13.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 13.3.1. Over-the-Counter (OTC) Drugs
  • 13.3.2. Prescription Drugs
• 13.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 13.4.1. Acute Pain
  • 13.4.2. Chronic Pain
• 13.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 13.5.1. Oral
  • 13.5.2. Parenteral
  • 13.5.3. Topical
  • 13.5.4. Others
• 13.6. Market Value Forecast By Indication, 2020 to 2035
  • 13.6.1. Arthritic Pain
  • 13.6.2. Bone Facture
  • 13.6.3. Cancer Pain
  • 13.6.4. Chronic Back Pain
  • 13.6.5. Fibromyalgia
  • 13.6.6. Migraine
  • 13.6.7. Muscle Sprain/Strain
  • 13.6.8. Neuropathic Pain
  • 13.6.9. Post-Operative Pain
  • 13.6.10. Others
• 13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 13.7.1. Hospital Pharmacies
  • 13.7.2. Retail Pharmacies
  • 13.7.3. Online Pharmacies
• 13.8. Market Value Forecast By Country, 2020 to 2035
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Drug Class
  • 13.9.2. By Drug Type
  • 13.9.3. By Pain Type
  • 13.9.4. By Route of Administration
  • 13.9.5. By Indication
  • 13.9.6. By Distribution Channel
  • 13.9.7. By Country

14. Europe Pain Management Therapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 14.2.1. Anticonvulsants
  • 14.2.2. Antidepressants
  • 14.2.3. Anaesthetics
  • 14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 14.2.5. Opioids
  • 14.2.6. Anti-migraine Agents
  • 14.2.7. Other
• 14.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 14.3.1. Over-the-Counter (OTC) Drugs
  • 14.3.2. Prescription Drugs
• 14.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 14.4.1. Acute Pain
  • 14.4.2. Chronic Pain
• 14.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 14.5.1. Oral
  • 14.5.2. Parenteral
  • 14.5.3. Topical
  • 14.5.4. Others
• 14.6. Market Value Forecast By Indication, 2020 to 2035
  • 14.6.1. Arthritic Pain
  • 14.6.2. Bone Facture
  • 14.6.3. Cancer Pain
  • 14.6.4. Chronic Back Pain
  • 14.6.5. Fibromyalgia
  • 14.6.6. Migraine
  • 14.6.7. Muscle Sprain/Strain
  • 14.6.8. Neuropathic Pain
  • 14.6.9. Post-Operative Pain
  • 14.6.10. Others
• 14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 14.7.1. Hospital Pharmacies
  • 14.7.2. Retail Pharmacies
  • 14.7.3. Online Pharmacies
• 14.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.8.1. Germany
  • 14.8.2. U.K.
  • 14.8.3. France
  • 14.8.4. Italy
  • 14.8.5. Spain
  • 14.8.6. Switzerland
  • 14.8.7. The Netherlands
  • 14.8.8. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Drug Class
  • 14.9.2. By Drug Type
  • 14.9.3. By Pain Type
  • 14.9.4. By Route of Administration
  • 14.9.5. By Indication
  • 14.9.6. By Distribution Channel
  • 14.9.7. By Country/Sub-region

15. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 15.2.1. Anticonvulsants
  • 15.2.2. Antidepressants
  • 15.2.3. Anaesthetics
  • 15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 15.2.5. Opioids
  • 15.2.6. Anti-migraine Agents
  • 15.2.7. Other
• 15.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 15.3.1. Over-the-Counter (OTC) Drugs
  • 15.3.2. Prescription Drugs
• 15.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 15.4.1. Acute Pain
  • 15.4.2. Chronic Pain
• 15.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 15.5.1. Oral
  • 15.5.2. Parenteral
  • 15.5.3. Topical
  • 15.5.4. Others
• 15.6. Market Value Forecast By Indication, 2020 to 2035
  • 15.6.1. Arthritic Pain
  • 15.6.2. Bone Facture
  • 15.6.3. Cancer Pain
  • 15.6.4. Chronic Back Pain
  • 15.6.5. Fibromyalgia
  • 15.6.6. Migraine
  • 15.6.7. Muscle Sprain/Strain
  • 15.6.8. Neuropathic Pain
  • 15.6.9. Post-Operative Pain
  • 15.6.10. Others
• 15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 15.7.1. Hospital Pharmacies
  • 15.7.2. Retail Pharmacies
  • 15.7.3. Online Pharmacies
• 15.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 15.8.1. China
  • 15.8.2. Japan
  • 15.8.3. India
  • 15.8.4. Australia & New Zealand
  • 15.8.5. South Korea
  • 15.8.6. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Drug Class
  • 15.9.2. By Drug Type
  • 15.9.3. By Pain Type
  • 15.9.4. By Route of Administration
  • 15.9.5. By Indication
  • 15.9.6. By Distribution Channel
  • 15.9.7. By Country/Sub-region

16. Latin America Pain Management Therapeutics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 16.2.1. Anticonvulsants
  • 16.2.2. Antidepressants
  • 16.2.3. Anaesthetics
  • 16.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 16.2.5. Opioids
  • 16.2.6. Anti-migraine Agents
  • 16.2.7. Other
• 16.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 16.3.1. Over-the-Counter (OTC) Drugs
  • 16.3.2. Prescription Drugs
• 16.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 16.4.1. Acute Pain
  • 16.4.2. Chronic Pain
• 16.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 16.5.1. Oral
  • 16.5.2. Parenteral
  • 16.5.3. Topical
  • 16.5.4. Others
• 16.6. Market Value Forecast By Indication, 2020 to 2035
  • 16.6.1. Arthritic Pain
  • 16.6.2. Bone Facture
  • 16.6.3. Cancer Pain
  • 16.6.4. Chronic Back Pain
  • 16.6.5. Fibromyalgia
  • 16.6.6. Migraine
  • 16.6.7. Muscle Sprain/Strain
  • 16.6.8. Neuropathic Pain
  • 16.6.9. Post-Operative Pain
  • 16.6.10. Others
• 16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 16.7.1. Hospital Pharmacies
  • 16.7.2. Retail Pharmacies
  • 16.7.3. Online Pharmacies
• 16.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Argentina
  • 16.8.4. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Drug Class
  • 16.9.2. By Drug Type
  • 16.9.3. By Pain Type
  • 16.9.4. By Route of Administration
  • 16.9.5. By Indication
  • 16.9.6. By Distribution Channel
  • 16.9.7. By Country/Sub-region

17. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 17.2.1. Anticonvulsants
  • 17.2.2. Antidepressants
  • 17.2.3. Anaesthetics
  • 17.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 17.2.5. Opioids
  • 17.2.6. Anti-migraine Agents
  • 17.2.7. Other
• 17.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 17.3.1. Over-the-Counter (OTC) Drugs
  • 17.3.2. Prescription Drugs
• 17.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 17.4.1. Acute Pain
  • 17.4.2. Chronic Pain
• 17.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 17.5.1. Oral
  • 17.5.2. Parenteral
  • 17.5.3. Topical
  • 17.5.4. Others
• 17.6. Market Value Forecast By Indication, 2020 to 2035
  • 17.6.1. Arthritic Pain
  • 17.6.2. Bone Facture
  • 17.6.3. Cancer Pain
  • 17.6.4. Chronic Back Pain
  • 17.6.5. Fibromyalgia
  • 17.6.6. Migraine
  • 17.6.7. Muscle Sprain/Strain
  • 17.6.8. Neuropathic Pain
  • 17.6.9. Post-Operative Pain
  • 17.6.10. Others
• 17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 17.7.1. Hospital Pharmacies
  • 17.7.2. Retail Pharmacies
  • 17.7.3. Online Pharmacies
• 17.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Drug Class
  • 17.9.2. By Drug Type
  • 17.9.3. By Pain Type
  • 17.9.4. By Route of Administration
  • 17.9.5. By Indication
  • 17.9.6. By Distribution Channel
  • 17.9.7. By Country/Sub-region

18. Competition Landscape

• 18.1. Market Player – Competition Matrix (By Tier and Size of companies)
• 18.2. Market Share Analysis By Company (2024)
• 18.3. Company Profiles
  • 18.3.1. Pfizer Inc.
    • 18.3.1.1. Company Overview
    • 18.3.1.2. Financial Overview
    • 18.3.1.3. Product Portfolio
    • 18.3.1.4. Business Strategies
    • 18.3.1.5. Recent Developments
  • 18.3.2. Eli Lilly and Company
    • 18.3.2.1. Company Overview
    • 18.3.2.2. Financial Overview
    • 18.3.2.3. Product Portfolio
    • 18.3.2.4. Business Strategies
    • 18.3.2.5. Recent Developments
  • 18.3.3. GSK plc
    • 18.3.3.1. Company Overview
    • 18.3.3.2. Financial Overview
    • 18.3.3.3. Product Portfolio
    • 18.3.3.4. Business Strategies
    • 18.3.3.5. Recent Developments
  • 18.3.4. Merck & Co., Inc.
    • 18.3.4.1. Company Overview
    • 18.3.4.2. Financial Overview
    • 18.3.4.3. Product Portfolio
    • 18.3.4.4. Business Strategies
    • 18.3.4.5. Recent Developments
  • 18.3.5. Novartis AG
    • 18.3.5.1. Company Overview
    • 18.3.5.2. Financial Overview
    • 18.3.5.3. Product Portfolio
    • 18.3.5.4. Business Strategies
    • 18.3.5.5. Recent Developments
  • 18.3.6. Johnson & Johnson Services, Inc.
    • 18.3.6.1. Company Overview
    • 18.3.6.2. Financial Overview
    • 18.3.6.3. Product Portfolio
    • 18.3.6.4. Business Strategies
    • 18.3.6.5. Recent Developments
  • 18.3.7. Abbott
    • 18.3.7.1. Company Overview
    • 18.3.7.2. Financial Overview
    • 18.3.7.3. Product Portfolio
    • 18.3.7.4. Business Strategies
    • 18.3.7.5. Recent Developments
  • 18.3.8. Teva Pharmaceutical Industries Ltd.
    • 18.3.8.1. Company Overview
    • 18.3.8.2. Financial Overview
    • 18.3.8.3. Product Portfolio
    • 18.3.8.4. Business Strategies
    • 18.3.8.5. Recent Developments
  • 18.3.9. Mallinckrodt Pharmaceuticals
    • 18.3.9.1. Company Overview
    • 18.3.9.2. Financial Overview
    • 18.3.9.3. Product Portfolio
    • 18.3.9.4. Business Strategies
    • 18.3.9.5. Recent Developments
  • 18.3.10. AstraZeneca
    • 18.3.10.1. Company Overview
    • 18.3.10.2. Financial Overview
    • 18.3.10.3. Product Portfolio
    • 18.3.10.4. Business Strategies
    • 18.3.10.5. Recent Developments
  • 18.3.11. Endo, Inc.
    • 18.3.11.1. Company Overview
    • 18.3.11.2. Financial Overview
    • 18.3.11.3. Product Portfolio
    • 18.3.11.4. Business Strategies
    • 18.3.11.5. Recent Developments
  • 18.3.12. Bayer AG
    • 18.3.12.1. Company Overview
    • 18.3.12.2. Financial Overview
    • 18.3.12.3. Product Portfolio
    • 18.3.12.4. Business Strategies
    • 18.3.12.5. Recent Developments
  • 18.3.13. Sanofi
    • 18.3.13.1. Company Overview
    • 18.3.13.2. Financial Overview
    • 18.3.13.3. Product Portfolio
    • 18.3.13.4. Business Strategies
    • 18.3.13.5. Recent Developments
  • 18.3.14. Viatris Inc
    • 18.3.14.1. Company Overview
    • 18.3.14.2. Financial Overview
    • 18.3.14.3. Product Portfolio
    • 18.3.14.4. Business Strategies
    • 18.3.14.5. Recent Developments
  • 18.3.15. Haleon plc
    • 18.3.15.1. Company Overview
    • 18.3.15.2. Financial Overview
    • 18.3.15.3. Product Portfolio
    • 18.3.15.4. Business Strategies
    • 18.3.15.5. Recent Developments
  • 18.3.16. Impax Laboratories, Inc.
    • 18.3.16.1. Company Overview
    • 18.3.16.2. Financial Overview
    • 18.3.16.3. Product Portfolio
    • 18.3.16.4. Business Strategies
    • 18.3.16.5. Recent Developments
  • 18.3.17. Lupin Limited
    • 18.3.17.1. Company Overview
    • 18.3.17.2. Financial Overview
    • 18.3.17.3. Product Portfolio
    • 18.3.17.4. Business Strategies
    • 18.3.17.5. Recent Developments